Genetic Agency Technology Conference (GATC) 2026
A one-day gathering where patients, AI pioneers, technologists, entrepreneurs, and therapeutic developers come together to co-create the future of genetic medicine
Hyatt Regency San Francisco Airport
About GATC
We are working to build a world with “genetic agency”: an individual’s ability to take action at the genetic level to live a healthier life. It’s a term we introduced to highlight the importance of creating therapeutic options where none exist today, and to recognize the efforts of patients and their families who work to develop these medicines themselves rather than to give up hope. To further the momentum, Dyno is hosting the 2nd Genetic Agency Technology Conference (GATC) in San Francisco on November 18.
The conference is inspired by a vision of the future with patient-empowering genetic technologies that are safe, effective and accessible to all – and the recognition that we will need to overcome major challenges, technological and otherwise, for all of these treatments to become a reality. This future can’t be realized by any one actor alone – it requires a community working together with pace to turn powerful emerging technologies into patient impact.
At GATC we’re bringing together leaders from various sectors: patients, AI pioneers, technologists, entrepreneurs, and therapeutic developers. Topics at this meeting will include patient stories, AI for sequence design and therapeutic development, frontier genetic technologies, along with challenges and opportunities of interest to attendees in preclinical development, manufacturing and regulatory pathways.
Compared to other conferences, GATC puts greater emphasis on technological frontiers, firmly grounded in patient impact and including highly participatory sessions emphasizing conversation and connection. Our assumption is that everyone who attends comes with expertise and a goal.
Why Attend
Empower
Hear from patients directly as co-creators shaping the next generation of genetic technologies
Connect
Meet your next collaborator and build lasting relationships across the gene therapy ecosystem, united by a shared commitment to genetic agency
Imagine
Step into the future with sessions that reveal the technology trends shaping what’s next
Activate
Leave with optimism and the conviction to act to realize a world with genetic agency
GATC 2025 in review
Last November, the inaugural GATC brought together 200 leaders in Boston, from patient advocates and therapeutic developers to technologists and regulators. Speakers included Victoria Gray, George Church, Sonia Vallabh, Terence Flotte, Sylke Poehling, and Allyson Berent. The result was a day of stimulating conversation, new connections, and energy to build a movement.
0+
attendees
0
unique speakers
0
talks
0+
minutes of open social time
Moments from GATC 2025
“The most valuable thing is the audience. The people here are just incredible, and it's been an amazing opportunity to learn from so many leaders in the field.”
Jeff Gerold
CEO, Rovanta
“The great thing is finding so many similar-minded people — thinking about the same things, facing the same challenges, discussing them together. Not necessarily having all the answers, but putting them out there to work through. It's very valuable.”
Julia Carrier
SVP, Eliquent Life Sciences
“I met so many people I follow online — and here I got to meet them in person. They willingly offered to help with the problems we're facing. The collaborative nature of this conference was the first time I've experienced anything like it. Really transformational.”
Ayush Ranawade
Co-founder, Nucleovir
“People are really encouraged to talk to each other, build relationships, find peer networks — you end up building the cohesive group that's needed to make change. The day is so thoughtfully architected.”
Winston Yan, MD, PhD
N=1 Collaborative
“Everyone here is the best in the field. It's remarkable to have everyone in one place talking about the future of genetics — from the molecular in the lab, to machine learning and AI.”
Omar Abudayyeh, PhD
Assistant Professor, Harvard Medical School
“This is technology with a purpose. Companies, patients, scientists, academics — everyone wants this one thing to happen, so you're comparing notes: okay, how do we get this done? A really refreshing type of conference to go to.”
Martin Borch Jensen, PhD
CSO, Gordian Biotechnology
“People didn't come with an agenda to close deals or fundraise. People came with a clear purpose: let's collaborate and find solutions together. Different competitors, different perspectives, working together — I admire it. The people selection was absolutely amazing.”
Yogev Debbi
Co-founder & CEO, Mana Bio
“It's amazing to be in a place where literally everyone is excited and driven to make sure genetic medicine works in a way that really helps patients. A concentrated event to find the right partners and the right stakeholders.”
Dan Oliver
CEO, Rejuvenate Bio
“It's really one of the most purposeful conferences I've attended in a long time. The first half of the day, they facilitated us meeting people we hadn't met before and talking through goals — it fostered more meaningful connections that are already translating into next steps.”
Samantha Piteri-Molina
Forge Biologics
“You normally don't see this group of people — entrepreneurs actually rolling up their sleeves and doing it. The network, the investment, the conversation, the fact that we're all in it together... it's an incredible part of it.”
Magdalena Tyrpien
CEO & Co-founder, Nionyx Bio
Speakers
Carolyn Bertozzi, PhD
Nobel Laureate, Stanford Professor & Co-founder Grace Science LLC
Matt Wilsey
CEO, Grace Science LLC
Joy Jiao, PhD
Life Sciences Research Lead, OpenAI
Špela Miroševič, PhD
Founding President, CTNNB1 Foundation
Jacob Stern
CEO, Team Sid & GP, Even One Ventures
Richard Wilson, MBA
Senior Vice President, Primary Focus Lead, Genetic Regulation, Astellas
Namrata Anand
Founder & CEO, Diffuse Bio
Robert Bell, PhD
Chief Scientific Officer, Ascidian Therapeutics
Andreas Borg
Founder at CURE5 Foundation and Full Stack Engineer at Jimini Health
Heidi Epstein
Vice Chair at Rett Syndrome Research Trust and Founder of Reverse Rett LA
Jake Heller
Co-founder, Brain Repair Foundation
Miki Heller
Co-founder, Brain Repair Foundation
Elliot Hershberg, PhD
Partner at Amplify and Author of The Century of Biology
Rich Horgan
Founder & CEO, Cure Rare Disease
Ian Huyett, JD
Associate Director & Head of Litigation, Cornerstone (New Hampshire)
Jainu Jogani
Co-founder, Child's Cure Genetic Research
Jo Kaur
Founder, Riaan Research Initiative
Alex LeNail, PhD
Postdoctoral Researcher at the Wyss Institute, Harvard Medical School
Boaz Levi, PhD
Co-founder & CEO, Epicure
Leszek Lisowski, PhD, MBA
Unit Head, Children's Medical Research Institute; Professor, University of Sydney
Ali Madani
Founder & CEO, Profluent
Alan Mardinly, PhD
Chief Scientific Officer, Science Corporation
William (Bill) Peranteau, MD
Fetal and Pediatric Surgeon, Children's Hospital of Philadelphia
Stanley Qi, PhD
Professor, Stanford University; Co-founder, Epicrispr Biotechnologies
Stevie Ringel
Founder & CEO at Nome, President at Kizuna Foundation
Giuseppe Ronzitti, PhD
Director of Research Strategy, Genethon; Research Director, Inserm
Pablo Sardi, PhD
Senior Vice President, Rare and Neurologic Diseases Research, Sanofi
Yiwei She, PhD
Founder & CEO, TNPO2 Foundation
Dean Suhr
President & Cofounder at MLD Foundation
Joseph Sullivan, MD
VP Clinical Development, Encoded Therapeutics
Ruxandra Teslo, PhD
Writer, Stripe Press
Yael Weiss, MD, PhD
Founder & CEO, Mahzi Therapeutics
Sajith Wickramasekara
Co-founder & CEO, Benchling
Schedule
November 18, 2026
8am - 5pm
5pm - 8pm
FAQ
Interested in taking part in GATC 2026?
GATC is an invitation-only event, though a limited number of spots are available for those who apply to attend. We welcome anyone interested to submit an application no later than August 14th.